Pfizer Inc (PFE) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pfizer Inc. is launching a Phase 2 trial to test how its drug etrasimod works in children with moderate to severe ulcerative colitis. The study, officially titled “A Phase 2 Open-Label, Single Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis,” aims to assess how well the drug controls disease activity and how safely it can be used in this young group.
The trial will test etrasimod, an oral drug taken once daily, designed to reduce inflammation in the gut. Pfizer plans to treat participants for up to 52 weeks, with an option to continue in a long term extension period of up to four additional years, giving the company a deeper view of durability and safety.
This is an interventional Phase 2 study with a single treatment arm, so every child in the trial receives etrasimod. There is no placebo group, and the trial is open label, meaning doctors and families know the treatment being given, with the main goal focused on treatment benefit rather than direct comparison.
The study is listed as “not yet recruiting,” with first and last update submissions dated March 10, 2026, signaling that start up activities are underway. Primary and final completion dates are not yet posted, but the planned 52 week treatment plus an extension of up to four more years suggests a long readout window before full data emerge.
For investors, this pediatric program expands the potential market for etrasimod beyond adults and could support a broader inflammatory bowel disease franchise if results are positive. The move positions Pfizer against other ulcerative colitis players, including AbbVie and Johnson & Johnson, and reinforces the ongoing race to secure share in younger patients where long term treatment value is high.
The study is currently in the setup phase and remains ongoing in planning, with more details and future updates available on the ClinicalTrials portal.
To learn more about PFE’s potential, visit the Pfizer Inc drug pipeline page.